Professor Matthew Cramp

Biography

Highlights

REF Impact Case Study
Reducing mortality from Hepatitis C virus

Publications

Key publications

Key publications are highlighted

Journals

Articles

Tavabie OD, Kronsten VT, Przemioslo R, McDougall N, Ramos K, Joshi D, Prachalias A, Menon K, Agarwal K & Heneghan MA (2023) 'Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study' Frontline Gastroenterology , DOI

Dhanda A, Bodger K, Hood S, Henn C, Allison M, Amasiatu C, Burton R, Cramp M, Forrest E & Khetani M (2022) 'The Liverpool alcohol‐related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for England' Alimentary Pharmacology & Therapeutics , DOI Open access

Nayagam JS, Nawaz A, Ramos K, Cramp ME, Shaw C, Shah S, Joshi D, Heaton N & Suddle A (2022) 'Renal dysfunction after liver transplantation for polycystic liver disease' Liver Transplantation 28, (10) 1674-1677 , DOI

Nayagam JS, Norton BC, Belete S, Rosinhas J, Ramos K, Cramp ME, O'Kane R, Cash WJ, Milan Z & Nicholson C (2022) 'Invasive coronary angiography as a tool in cardiac evaluation for liver transplant candidates' Journal of Liver Transplantation 7, , DOI Open access

Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, Waked I, Dore GJ, Abbas Z & Abdallah AR (2022) 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study' The Lancet Gastroenterology & Hepatology 7, (5) 396-415 , DOI

Tanase A, Dhanda A, Cramp M, Streeter A & Aroori S (2022) 'A UK survey on variation in the practice of management of choledocholithiasis and laparoscopic common bile duct exploration (ALiCE Survey)' Surgical Endoscopy 36, (8) 5882-5896 , DOI Open access

Dhanda AD, Felmlee D, Boeira P, Moodley P, Tan H, Scalioni LDP, Lilly K, Sheridan DA & Cramp ME (2022) 'Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype' Immunobiology 227, (2) , DOI Open access

Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor S-S & Gervais O (2022) 'Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]' Journal of Hepatology 76, (2) 489-489 , DOI

Valencia A, Vergara C, Thio CL, Vince N, Douillard V, Grifoni A, Cox AL, Johnson EO, Kral AH & Goedert JJ (2022) 'Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1' The American Journal of Human Genetics 109, (2) 299-310 , DOI

Ahmed W, Kyle D, Khanna A, Devlin J, Reffitt D, Zeino Z, Webster G, Phillpotts S, Gordon R & Corbett G (2022) 'Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience' Therapeutic Advances in Gastroenterology 15, , DOI Open access

Alsaleh M, Leftley Z, O’Connor T, Hughes T, Barbera TA, Koomson LK, Zabron A, Reeves H, Cramp M & Ryder SD (2021) 'Mapping of population disparities in the cholangiocarcinoma urinary metabolome' Scientific Reports 11, (1) , DOI Open access

Pradeep A, Barker F, Ramos K, Littlejohn W, Tavabie OD, Nicholson C, Menon K, Cramp ME, McDougall N & Cash J (2021) 'Virtual liver transplant assessment: a novel pathway that is likely safe, effective and optimises access to transplantation' Frontline Gastroenterology 13, (4) 360-362 , DOI

Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor S-S & Gervais O (2021) 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' Journal of Hepatology 75, (3) 572-581 , DOI Open access

Nayagam JS, Tavabie OD, Norton B, McMahon MJS, Ramos K, Cadden ISH, Cramp ME, Menon K, Prachalias A & Agarwal K (2021) 'Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals' Journal of Liver Transplantation 3, , DOI Open access

Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DE, Nakamura M, Ueno K & Hitomi Y (2021) 'X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis' Gastroenterology 160, (7) 2483-2495.e26 , DOI

Aranday-Cortes E, McClure CP, Davis C, Irving WL, Adeboyejo K, Tong L, da Silva Filipe A, Sreenu V, Agarwal K & Mutimer D (2021) 'Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa' The Journal of Infectious Diseases , DOI Open access

Vergara C, Duggal P, Thio CL, Valencia A, O’Brien TR, Latanich R, Timp W, Johnson EO, Kral AH & Mangia A (2020) 'Correction: Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection' Genes & Immunity 21, (6-8) 420-420 , DOI

Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K & Mutimer D (2020) 'Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection' Journal of Viral Hepatitis 28, (1) 168-176 , DOI Open access

Vergara C, Valencia A, Thio CL, Goedert JJ, Mangia A, Piazzolla V, Johnson E, Kral AH, O’Brien TR & Mehta SH (2020) 'A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' The Journal of Infectious Diseases 223, (12) 2090-2098 , DOI

Vergara C, Duggal P, Thio CL, Valencia A, O’Brien TR, Latanich R, Timp W, Johnson EO, Kral AH & Mangia A (2020) 'Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection' Genes & Immunity 21, (5) 348-359 , DOI

Tan HK, Streeter A, Cramp ME & Dhanda AD (2020) 'Effect of zinc treatment on clinical outcomes in patients with liver cirrhosis: A systematic review and meta-analysis' World Journal of Hepatology 12, (7) 389-398 , DOI Open access

Dhanda A, Atkinson S, Vergis N, Enki D, Fisher A, Clough R, Cramp M & Thursz M (2020) 'Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis' Alimentary Pharmacology & Therapeutics , DOI Open access

Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S & Menon K (2020) 'Adult liver transplantation: A UK clinical guideline - part 1: pre-operation' Frontline Gastroenterology 11, (5) 375-384 , DOI Open access

Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S & Menon K (2020) 'Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation' Frontline Gastroenterology 11, (5) 385-396 , DOI Open access

Sánchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L & Heward J (2020) 'Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation' American Journal of Transplantation 20, (4) 1125-1136 , DOI Open access

Lim TY, McPhail MJ, Shah A, Mahgoub S, Nayagam J, Cramp M, Bernal W, Menon K, Jassem W & Joshi D (2020) 'Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction' Transplantation Direct 6, (2) , DOI Open access

Alsaleh M, Leftley Z, Barbera TA, Koomson LK, Zabron A, Crossey MME, Reeves HL, Cramp M, Ryder S & Greer S (2020) 'Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort' Journal of Clinical and Experimental Hepatology 10, (1) 17-29 , DOI

Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, Baker A, Batterham R, Brown K & Burton R (2020) 'Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK' The Lancet 395, (10219) 226-239 , DOI

Dhanda AD, Williams EL, Yates E, Lait PJP, Schewitz-Bowers LP, Hegazy D, Cramp ME, Collins PL & Lee RWJ (2019) 'Intermediate Monocytes in Acute Alcoholic Hepatitis Are Functionally Activated and Induce IL-17 Expression in CD4+ T Cells' The Journal of Immunology 203, (12) 3190-3198 , DOI

Dhanda AD, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ & Cramp ME (2019) 'Ex Vivo T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis' Gut and Liver , DOI Open access

Norton BC, Srivastava A, Ramos K, Vine L, Taylor R, Aluvihare V, Heaton N & Cramp ME (2019) 'Risk-adjusted survival in liver transplant patients assessed and managed by a non-transplanting centre: South West Liver Unit experience' Frontline Gastroenterology 11, (3) 202-208 , DOI

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K & Lahser F (2019) 'Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6' Journal of Viral Hepatitis , DOI

Bennett K, Enki DG, Thursz M, Cramp ME & Dhanda AD (2019) 'Systematic review with meta‐analysis: high mortality in patients with non‐severe alcoholic hepatitis' Alimentary Pharmacology and Therapeutics , DOI Open access

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M & Rodriguez CF (2019) 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis' Journal of Hepatology 71, (4) 660-665 , DOI Open access

Alsaleh M, Barbera T, Reeves H, Cramp M, Ryder S, Gabra H, Nash K, Shen Y-L, Holmes E & Williams R (2019) '<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>' Hepatic Medicine: Evidence and Research 11, 47-67 , DOI Open access

Vergara C, Thio CL, Johnson E, Kral AH, O’Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH & Kirk GD (2019) 'Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus' Gastroenterology 156, (5) 1496-1507.e7 , DOI

Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A, Burton R & Cramp ME (2018) 'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 392, (10162) 2398-2412 , DOI

Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA & Jones DEJ (2018) 'Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom' Alimentary Pharmacology and Therapeutics 48, (9) 951-960 , DOI Open access

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F & Cardinale V (2018) 'Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score' The Lancet Gastroenterology & Hepatology 3, (9) 626-634 , DOI

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM (2018) 'Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial' Hepatology 67, (6) 2113-2126 , DOI

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N & Dhawan A (2017) 'Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 391, (10125) 1097-1107 , DOI

Ow MM, Hegazy D, Warshow UM & Cramp ME (2017) 'Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood' Journal of Viral Hepatitis 25, (3) 245-253 , DOI Open access

Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S & Aneja J (2017) 'Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection' Scientific Reports 7, Author Site , DOI Open access

Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME (2017) 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 , DOI Open access

Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME (2017) 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis , DOI Open access

Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, Roudot-Thoraval F, Craxi A, Manns M & Marinho RT (2017) 'Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study' The Lancet Gastroenterology & Hepatology 2, (5) 325-336 , DOI

Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A, Dillon J & Dyson J (2017) 'New metrics for the Lancet Standing Commission on Liver Disease in the UK' The Lancet 389, (10083) 2053-2080 , DOI

Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, Waked I, Alavian SM, Lee M-H & Negro F (2017) 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study' The Lancet Gastroenterology & Hepatology 2, (3) 161-176 , DOI

Dhanda AD, Sinha A, Hunt V, Saleem S, Cramp ME & Collins PL (2017) 'Infection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids' World Journal of Gastroenterology 23, (11) 2052-2052 , DOI Open access

Acevedo JG & Cramp ME (2017) 'Hepatorenal syndrome: Update on diagnosis and therapy' World Journal of Hepatology 9, (6) 293-293 , DOI Open access

Shariff MIF, Kim JU, Ladep NG, Crossey MME, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S & Greer S (2016) 'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy' Journal of Clinical and Experimental Hepatology 6, (3) 186-194 , DOI

Swann RE, Mandalou P, Robinson MW, Ow MM, Foung SKH, McLauchlan J, Patel AH & Cramp ME (2016) 'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection' Journal of Viral Hepatitis 23, (11) 873-880 , DOI Open access

Vine LJ, Sieberhagen C & Cramp ME (2015) 'Diagnosis and management of hepatitis C' British Journal of Hospital Medicine 76, (11) 625-630 , DOI

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J & Dyson J (2015) 'Implementation of the Lancet Standing Commission on Liver Disease in the UK' The Lancet 386, (10008) 2098-2111 , DOI

Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P & Williamson K (2015) 'The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis' Hepatology 63, (3) 930-950 , DOI

Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D & Qian DC (2015) 'International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways' Nature Communications 6, (1) , DOI Open access

Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG & Cramp ME (2015) 'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV' J Med Virol 87, (7) 1207-1217 Author Site , DOI

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H & Clements A (2015) 'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact' JOURNAL OF VIRAL HEPATITIS 22, (4) 399-408 Author Site , DOI Open access

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G & Gilmore I (2014) 'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis' Lancet 384, (9958) 1953-1997 Author Site , DOI

Ow MMG, Erasmus P, Minto G, Struthers R, Joseph M, Smith A, Warshow UM, Cramp ME & Cross TJS (2014) 'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation' Liver Transpl 20, (9) 1081-1088 Author Site , DOI

Jothimani D, Cramp ME & Cross TJS (2014) 'Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study' J Clin Exp Hepatol 4, (3) 221-225 Author Site , DOI

Cramp ME, Rosenberg WM, Ryder SD, Blach S & Parkes J (2014) 'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality' BMC Gastroenterol 14, Author Site , DOI Open access

Houldsworth A, Metzner M, Shaw S, Kaminski E, Demaine AG & Cramp ME (2014) 'Polymorphic differences in SOD-2 may influence HCV viral clearance' J Med Virol 86, (6) 941-947 Author Site , DOI

Bruggmann P, Berg T, Øvrehus ALH, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD & Sperl J (2014) 'Historical epidemiology of hepatitis C virus (HCV) in selected countries' J Viral Hepat 21 Suppl 1, 5-33 Author Site , DOI

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M & Akarca U (2014) 'Strategies to manage hepatitis C virus (HCV) disease burden' J Viral Hepat 21 Suppl 1, 60-89 Author Site , DOI

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C & Lázaro P (2014) 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm' J Viral Hepat 21 Suppl 1, 34-59 Author Site , DOI

Houldsworth A, Metzner MM, Demaine A, Hodgkinson A, Kaminski E & Cramp M (2014) 'CD81 sequence and susceptibility to hepatitis C infection' JOURNAL OF MEDICAL VIROLOGY 86, (1) 162-168 Author Site , DOI

Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, Hydes TJ, Cramp ME, Alexander G & Little A-M (2013) 'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection' Hepatology 58, (3) 881-889 Author Site , DOI

Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT & Peters MG (2013) 'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts' Ann Intern Med 158, (4) 235-245 Author Site , DOI

Saunders M, Sieberhagen C, Taylor L, Fry F, McKenna M, Needs S, Chimakurthi R & Cramp M (2012) 'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION' GUT 61, A140-A141 Author Site , DOI

Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S & Cramp ME (2012) 'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection' J Viral Hepat 19, (7) 501-508 Author Site , DOI

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM (2012) 'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis' Eur J Gastroenterol Hepatol 24, (5) 543-550 Author Site , DOI

Roberts L, Cramp M & Montague I (2012) 'Cholestasis secondary to progesterone' Archives of Disease in Childhood - Fetal and Neonatal Edition 97, (Suppl 1) A69.3-A69 , DOI

Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI (2011) 'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection' Gut 60, (Suppl 2) A51-A52 , DOI

Warshow U, Sieberhagen C, Hegazy D, Kaminski E, Knapp S, Khakoo S & Cramp ME (2011) 'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection' Gut 60, (Suppl 2) A21-A22 , DOI

Petrova M, Fung M, Cramp ME, Mitchell JD & Cross TJS (2011) 'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience' Gut 60, (Suppl 2) A37-A37 , DOI

Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, Alexander G, Thursz M, Cramp M & Khakoo SI (2011) 'A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection' GASTROENTEROLOGY 141, (1) 320-U419 Author Site , DOI

Jothimani D, Cramp ME, Mitchell JD & Cross TJS (2011) 'Treatment of autoimmune hepatitis: a review of current and evolving therapies' J Gastroenterol Hepatol 26, (4) 619-627 Author Site , DOI

Thurairajah PH, Hegazy D, Demaine A, Kaminski ER & Cramp ME (2011) 'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation' J Infect Dis 203, (6) 847-853 Author Site , DOI

Jothimani D, Jothimani D, Warshow U, Barnardo A, Cramp M, Mitchell J & Cross T (2010) 'P14 Mycophenolate mofetil in patients with autoimmune hepatitis intolerant to azathioprine' Gut 59, (Suppl 2) , DOI

Tanwar S, Wright M, Foster G, Ryder S, Mills P, Cramp M, Parkes J & Rosenberg W (2010) 'P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection' Gut 59, (Suppl 2) , DOI

Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little A-M, Alexander GJ, Rosenberg WMC & Cramp ME (2010) 'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus' HEPATOLOGY 51, (4) 1168-1175 Author Site , DOI

Rashid M, Mitchell JD, Cramp ME & Cross TJS (2010) 'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C' HEPATOLOGY 51, (1) 354-355 Author Site , DOI

Cross TJS, Mitchell JD & Cramp ME (2009) 'Elastography for the non-invasive assessment of liver disease: limitations and future developments' GUT 58, (8) 1171-1172 Author Site

Marcellin P, Reesink H, Berg T, Cramp M, Flisiak R, Van Vlierberghe H, Verloes R, Lenz O, Peeters M & Sekar V (2009) 'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY' JOURNAL OF HEPATOLOGY 50, S385-S385 Author Site , DOI

Hegazy D, Thurairajah P, Metzner M, Houldsworth A, Shaw S, Kaminski E, Demaine AG & Cramp ME (2008) 'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection' Clin Exp Immunol 152, (3) 538-541 Author Site , DOI

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M & Stein K (2008) 'Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis' Br J Cancer 98, (7) 1166-1175 Author Site , DOI Open access

Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K (2007) 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technol Assess 11, (34) 1-206 Author Site , DOI

Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A & Stein K (2007) 'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis' Health Technology Assessment 11, (34) 1-+

Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U & Stein K (2006) 'Case finding for hepatitis C in primary care: a cost utility analysis' Fam Pract 23, (4) 393-406 Author Site , DOI

Clark SJ, Creighton S, Horner M, Smith HM, Portmann B, Taylor C & Cramp ME (2006) 'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression' Int J STD AIDS 17, (1) 67-69 Author Site , DOI

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K (2006) 'The cost-effectiveness of testing for hepatitis C in former injecting drug users' Health Technology Assessment 10, (32) 1-+

Awasthi AK & Cramp ME (2005) 'Hepatic hydrothorax' Br J Hosp Med (Lond) 66, (9) 540-541 Author Site , DOI

Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG & Cramp ME (2005) 'Polymorphisms in the IL-12B gene and outcome of HCV infection' J Interferon Cytokine Res 25, (5) 271-276 Author Site , DOI

Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Dalton HR, Harrison TJ, Hill SF & MacFarlane L (2005) 'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics' Journal of Infectious Diseases 192, (7) 1166-1172

Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D & Hilgartner M (2004) 'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection' Science 305, (5685) 872-874 Author Site , DOI

Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, Williams R & Naoumov NV (2004) 'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity' J Med Virol 72, (3) 370-376 Author Site , DOI

Horne JA, Clements AJ, Drennan P, Stein K & Cramp ME (2004) 'Screening for hepatitis C virus in the Dartmoor prison population: an observational study' Journal of Public Health 26, (4) 372-375

Kyrlagkitsis L, Portmann B, Smith H, O'Grady J & Cramp ME (2003) 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' AMERICAN JOURNAL OF GASTROENTEROLOGY 98, (7) 1588-1593 Author Site , DOI

Kyrlagkitsis I, Portmann B, Smith H, O'Grady J & Cramp ME (2003) 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT' Am J Gastroenterol 98, (7) 1588-1593 Author Site , DOI

Metzner M, Maulayah P, Benshemesh C & Cramp ME (2003) 'Traditional Chinese medicine in the treatment of chronic HCV infection' Gut 52, (5)

HOULDSWORTH A, METZNER M, ROSSOL S, KAMINSKI E, DEMAINE A & CRAMP M (2003) '407 IL-12 gene polymorphism and outcome of HCV infection' Hepatology 38, 356-356 , DOI

Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, McFarlane IG, Cramp ME & Donaldson PT (2002) 'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy' Liver 22, (5) 404-412 Author Site , DOI

Katona SJ, Cooper PC, Cramp ME & Kaminski ER (2002) 'Re: Whither smooth muscle antibodies in the third millennium?' J Clin Pathol 55, (7) 558-559 Author Site , DOI

Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA & Cramp ME (2002) 'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases' J Hepatol 36, (2) 295-301 Author Site , DOI

Saravanan R & Cramp ME (2002) 'Investigation and treatment of ascites' Clin Med (Lond) 2, (4) 310-313 Author Site , DOI

Kyrlagkitsis I, Cramp ME, Smith H, Portmann B & O'Grady J (2002) 'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center' Hepatogastroenterology 49, (44) 524-528 Author Site

Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O'Grady J & Rela M (2001) 'Liver transplantation in adults coinfected with HIV' Transplantation 72, (10) 1684-1688 Author Site , DOI

Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O???Grady J & Rela M (2001) 'Liver Transplantation in Adults Coinfected With HIV. Transplantation 2001; 72: 1684' Transplantation 72, (10) 1594-1595 , DOI

Kyrlagkitsis I, Portmann B & Cramp ME (2000) 'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT' HEPATOLOGY 32, (4) 285A-285A Author Site

Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MH (2000) 'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)' J Am Acad Dermatol 43, (2 Pt 2) 403-408 Author Site , DOI

Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, Potter M & Rustin MHA (2000) 'Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)' Journal of the American Academy of Dermatology 43, (2) 403-408 , DOI

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV (2000) 'Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C' Gastroenterology 118, (2) 346-355 Author Site , DOI

Cramp ME (1999) 'HBV + HCV = HCC?' Gut 45, (2) 168-169 Author Site , DOI

Cramp ME (1999) 'HBV plus HCV=HCC?' GUT 45, (2) 168-169 Author Site , DOI

Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F & Vogel W (1999) 'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre' Gut 44, (4) 563-567 Author Site , DOI

Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R & Naoumov NV (1999) 'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia' Gut 44, (3) 424-429 Author Site , DOI

Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R & Donaldson PT (1998) 'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia' J Hepatol 29, (2) 207-213 Author Site , DOI

Cramp ME, Rossol S, Carucci P, Williams R, Naoumov NV & Donaldson PT (1998) 'The influence of the HLA class II allele DQB1∗0301 on HCV specific T helper cell responses' Journal of Hepatology 28, 94-94 , DOI

Cramp M (1997) 'Book Review: Diseases of the Liver and Biliary System' Journal of the Royal Society of Medicine 90, (10) 584-584 , DOI

CRAMP ME & WILLIAMS R (1997) 'Hepatitis in alcohol and drug misusers: practical issues' Addiction Biology 2, (4) 411-420 , DOI

Cramp ME, Grundy HC, Perinpanayagam RM & Barnado DE (1996) 'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults' J R Soc Med 89, (7) 401-402 Author Site

Cramp ME, Hing MC, Marriott DJ, Freund J & Cooper DA (1996) 'Bile acid malabsorption in HIV infected patients with chronic diarrhoea' Aust N Z J Med 26, (3) 368-371 Author Site , DOI

Inwald D, Nelson M, Cramp M, Francis N & Gazzard B (1994) 'Cutaneous manifestations of mycobacterial infection in patients with AIDS' Br J Dermatol 130, (1) 111-114 Author Site , DOI

Cramp ME, Hickey MM & Gazzard MM (1993) 'Re-emergence of tuberculosis' BMJ 306, (6882) Author Site , DOI

Grange JM & Yates MD (1993) 'Re-emergence of tuberculosis' BMJ 306, (6882) 931-932 , DOI

Collins CD, Blanshard C, Cramp M, Gazzard B & Gleeson JA (1992) 'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection' Clin Radiol 46, (6) 410-411 Author Site , DOI

Tattersall JE, Cramp M, Shannon M, Farrington K & Greenwood RN (1992) 'Rapid high-flux dialysis can cure uraemic peripheral neuropathy' Nephrol Dial Transplant 7, (6) 539-540 Author Site

Chapters

Cramp M, Dhanda A & Naoumov NV (2020) 'Hepatitis viruses (excluding hepatitis C virus)' Oxford Textbook of Medicine Oxford University PressOxford 889-C8.5.21.P45 , DOI

Cyril S & Cramp ME (2013) 'Clinical and Pathological Features, and Diagnosis' Viral Hepatitis John Wiley & Sons, Ltd 442-449 , DOI

Palmer DH & Cramp ME (2011) 'Systemic Therapy for Hepatocellular Carcinoma: Future Directions' Wiley 199-211 , DOI

Conference Papers

Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM (2016) 'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks' 39A-40A

Agarwal K, Schultz M, Pianko S, Bank L, Collier J, George J, Priest M, Ryder SD, Burman BE & Cheent K (2016) 'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin' 455A-456A

Ahmed A, Dhanda A, Hegazy D, Felmlee D, Sheridan D & Cramp M (2016) 'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype' 745A-745A

Jothimani D, Govil S, Vij M, Sheridan D, Cramp M & Rela M (2016) 'Predicting Fatty Liver Disease in Healthy Potential Liver Donors' Elsevier BV S479-S479 , DOI

Asselah T, Shafran S, Bourgeois S, Lai C-L, Cramp M, Mathurin P, Willems B, Nguyen MH, Davis MN & Huang KC (2016) 'SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)' S827-S828

Mandalou P, Robinson MW, Felmlee D, Sieberhagen C, Mindos T, Hegazy D, MacLaughlan J & Cramp ME (2015) 'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv' BMJ A452.1-A452 , DOI

Norton BC, Adebayo D, Ramos K, Smith A & Cramp M (2015) 'PTH-124 Liver transplant outcomes in patients with care devolved to a non-transplanting centre: south west liver unit experience' BMJ A462.2-A463 , DOI

Dhar A, Tschotazis E, Brown R, Manousou P, Millson C, Aldersley M, Forbes S, Aggarwal K, Gera A & Cramp M (2015) 'LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year' Elsevier BV S268-S269 , DOI

Ow M, Hegazy D & Cramp ME (2014) 'P210 ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY' Elsevier BV S136-S136 , DOI

Rosenberg WM, Cramp M, Davis M, Parkes J, Ryder S, Razavi H & Hindman S (2014) 'P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND' Elsevier BV S333-S334 , DOI

Ow MM, Hegazy D, Warshow U & Cramp ME (2014) 'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity' 1064A-1064A

Mandalou P, Swann R, Patel AH & Cramp ME (2014) 'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV' 1057A-1057A

Martin NK, Vickerman P, Clements A, Cramp M, De Angeles D, Dillon JF, Fahey S, Foster GR, Goldberg DJ & Gordon F (2013) 'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS' S356-S356 , DOI

Joseph M, Erasmus P, Minto G, Mitchell J, Cramp M & Cross TJ (2013) 'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES' S412-S412 , DOI

Petrova M, Fung M & Cramp M (2012) 'HPS AND INTRAPULMONARY VASCULAR SHUNTS IN LIVER TRANSPLANT CANDIDATES' S254-S254 , DOI

Ashraf S, Knapp S, Becford-Tackoir C, Brooks C, Little A-M, Alexander G, Cramp M & Khakoo SI (2011) 'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection' 173-173

Warshow U, Sieberhagen C, Hegazy DM, Kaminski E, Knapp S, Khakoo S & Cramp ME (2011) 'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION' 1322A-1322A

Knapp S, Ho KM, Warshow U, Heqazy D, Little A-M, Alexander G, Thursz M, Cramp ME & Khakoo SI (2011) 'ABSENCE OF IL-28B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION' S38-S39 , DOI

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM (2010) 'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE' 710A-711A

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J & Rosenberg WM (2010) 'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION' 710A-710A

Sieberhagen C, Brown ASM, Demuth DG, Livingstone JA & Cramp ME (2010) 'PREDICTORS OF HEPATITIS C TREATMENT OUTCOME IN GENOTYPE 1 PATIENTS IN A "REAL WORLD" SETTING' A77-A77 , DOI

Warshow U, Knapp S, Brackenbury LS, Hegazy D, Thurairajah PH, Khakoo S & Cramp ME (2009) 'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION' 386A-386A

Hegazy D, Edwards P, Warshow U & Cramp ME (2009) 'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES' 950A-950A

Warshow U, Riva A, Thurairajah PH, Hegazy D, Chokshi S & Cramp ME (2009) 'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION' 936A-936A

Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME (2009) 'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' A17-A17

Thurairajah P, Warshow U, Demaine A, Kaminski E, Hegazy D & Cramp ME (2009) 'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS' S326-S326 , DOI

Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV & Cramp ME (2008) 'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection' United States 1749-1755 , DOI

Barnardo AT, Walters L, Cramp M & Mitchell J (2008) 'Audit of management of alcohol withdrawal at derriford hospital' A72-A72

Barnardo AT, Warshow U, Mitchell J & Cramp M (2008) 'Mycophenolate mofetil in patients with refractory autoimmune hepatitis' A71-A72

Thurairajah PH, Hegazy DM, Richardon SJ, Demaine AG, Kaminski ER & Cramp ME (2007) 'HCV-specific cellular immune responses in intravenous drug users without HCV infection' 240A-241A

Hegazy DM, Thurairajah PH, Metzner M, Houldsworth A, Kaminski E, Demaine A & Cramp ME (2007) 'Interleukin 12B gene polymorphism and apparent resistance to HCV infection' 890A-891A

Thurairajah PH, Hegazy D, Kaminski E, Demaine A & Cramp ME (2007) 'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection' A134-A135

Thurairajah PH, Hegazy D, Kaminski E, Demaine A, Cunningham R & Cramp ME (2006) 'Late spontaneous clearance of hepatitis C' A43-A43

Houldsworth A, Metzner M, Demaine AG, Kaminski E & Cramp ME (2005) 'CD81 sequence and susceptibility to HCV infection' A47-A47

Metzner M, Houldsworth A, Demaine AG, Kaminski E & Cramp ME (2005) 'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV' A6-A7

Metzner MK, Houldsworth A, Demaine A, Kaminski E & Cramp ME (2005) 'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV' A712-A712 Open access

Beckly JB, Jackson S, Cramp ME & Beckly DE (2004) 'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks' A44-A44

Houldsworth A, Metzner M, Rossol S, Kaminski E, Demaine AG & Cramp ME (2003) 'IL-12 gene polymorphism and outcome of HCV infection' 356A-356A

Kyrlagkitsis I, Metzner M, Smith H, Depla E, Sablon E & Cramp ME (2003) 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'

Kyrlagkitsis I, Metzner MK, Smith H, Depla E, Sablon E & Cramp ME (2002) 'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA' 552A-552A

Metzner MK, Maulayah P, Benshemesh C & Cramp ME (2002) 'Traditional Chinese medicine in the treatment of chronic HCV infection' 569A-569A

Clark SJ, Creighton S, Horner M, Portmann BC, Cramp M & Taylor C (2000) 'Reactivation of latent hepatitis B virus infection with HIV related immunosuppression' 454A-454A

Clare MA, Portmann BC & Cramp ME (1999) 'The association of the Arg25Pro polymorphism in the TGF beta 1 gene with fibrosis in chronic hepatitis C patients' 331A-331A

Cramp ME, Maertens G, O'Grady J & Rossol S (1999) 'HCV-specific immune responses in HCV exposed but uninfected cases' A97-A97

Cramp ME & Rossol S (1998) 'HCV-specific T helper cell responses in HCV exposed but uninfected cases' 200A-200A

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV (1998) 'HLA class III and class II alleles in hepatitis C virus infection and outcome' 159-160

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV (1998) 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 155-155

Torre F, Cramp M, Owsianka A, Carman W, Williams R & Naoumov NV (1998) 'Mutations within a promiscuous immunodominant epitope in hepatitis B core protein and their effect on T helper cell response' 156-157

Cramp ME, Rossol S, Carucci P, Williams R, Naoumov NV & Donaldson PT (1998) 'The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses' A21-A21

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R & Naoumov NV (1997) 'Interferon induced virus specific T helper cell responses are associated with viral clearance in chronic HCV infection' 1111-1111

Rossol S, Cramp ME, Carucci P, Singer MV, Williams R & Naoumov NV (1997) 'Reduced production of interleukin-12 by PBMC from patients with chronic hepatitis C' 1121-1121

Torre F, Cramp ME, Owsianka A, Carman W, Williams R & Naoumov NV (1997) 'T helper cell response to mutations within a promiscuous immunodominant epitope in acute and chronic hepatitis B' 1953-1953

Bernal W, Cramp M, Underhill JA, Carucci P & Donaldson PT (1997) 'Tumor necrosis factor gene polymorphisms in hepatitis C virus infection' 1413-1413

Cramp ME, Chokshi S, Tzampouras N, Torre F, Williams R & Naoumov NV (1997) 'Beneficial in vitro effects of tucaresol on the immune response to hepatitis C virus' TH119-TH119

Cramp ME, Carucci P, Chokshi S, Rossol S, Donaldson PT, Williams R & Naoumov NV (1996) 'A multispecific T lymphocyte response to hepatitis C virus proteins occurs in patients with viral clearance and persists many years after exposure' 503-503

Cramp ME, Carucci P, Donaldson PT, Underhill J, Tibbs C, Naoumov NV & Williams R (1996) 'Evidence that HLA class II genotype may be associated with clearance of hepatitis C virus' 99-99

Reports

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A & Stein K (2006) The cost-effectiveness of testing for hepatitis C in former injecting drug users. Author Site , DOI

Presentations and posters

Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, Subramanian M & Myers RP Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, Subramanian M & Myers RP 'Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial' Author Site

Yates E, Cramp M & Dhanda A Yates E, Cramp M & Dhanda A 'A NOVEL FUNCTIONAL BIOASSAY PREDICTS 90-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS' Author Site , DOI Open access

Tanase A, Aroori S, Dhanda A, Cramp M & Streeter A Tanase A, Aroori S, Dhanda A, Cramp M & Streeter A 'A UK Survey on Variation in Practice of Management of Choledocholithiasis and Laparoscopic Common Bile Duct Exploration (ALiCE Survey)' , DOI

Bridge S, Pagano S, Sheridan D, Lodge J, Cramp M, Taylor-Robinson S, Neely D, Vuilleumier N & Bassendine M Bridge S, Pagano S, Sheridan D, Lodge J, Cramp M, Taylor-Robinson S, Neely D, Vuilleumier N & Bassendine M 'Autoantibodies to apolipoprotein A-1 in chronic hepatitis C infection: a role in hepatic fibrosis and cirrhosis?' , DOI

Dhanda A, Yates E & Cramp M Dhanda A, Yates E & Cramp M 'Corticosteroid treatment is associated with a resolution of altered CD4+ T cell phenotype in patients with severe alcoholic hepatitis' , DOI

Haber B, Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD & Ustianowski A Haber B, Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD & Ustianowski A 'Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study' , DOI

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 'Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study' , DOI

Tavabie O, Kronsten V, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Prachalias A, Menon K & Agarwal K Tavabie O, Kronsten V, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Prachalias A, Menon K & Agarwal K 'Formal referral networks optimise patient selection for liver transplantation' , DOI

Tavabie O, Nayagam J, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Agarwal K, Heneghan M & Aluvihare V Tavabie O, Nayagam J, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Agarwal K, Heneghan M & Aluvihare V 'Inequality in access to liver transplant: are satellite liver transplant centres the answer?' , DOI

Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M Dhanda A, Williams E, Yates E, Collins P, Lee R & Cramp M 'Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16−) monocytes' , DOI

Bennett K, Viayna E, Gunal M, Stacey D, Davis A, Southern D & Cramp M Bennett K, Viayna E, Gunal M, Stacey D, Davis A, Southern D & Cramp M 'Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model' , DOI

Bennett K, Enki D, Thursz M, Cramp M & Dhanda A Bennett K, Enki D, Thursz M, Cramp M & Dhanda A 'OTU-11 Non-severe alcoholic hepatitis is not a benign condition: systematic review and meta-analysis of mortality data' , DOI

Tan H, Cramp M & Dhanda A Tan H, Cramp M & Dhanda A 'P026 Differential epigenetic regulation in survivors and non-survivors from severe alcoholic hepatitis' , DOI

Tan H, Boeira P, Cramp M & Dhanda A Tan H, Boeira P, Cramp M & Dhanda A 'P03 Mortality from severe alcoholic hepatitis is associated with increased oxidative stress and epigenetic alterations' , DOI

Bennett K, Viayna E, Stacey D, Southern D & Cramp M Bennett K, Viayna E, Stacey D, Southern D & Cramp M 'P044 Healthcare recourse use in patients with cirrhotic ascites: a UK real world evidence study' , DOI

Pradeep A, Barker F, Ramos K, Littlejohn W, Tavabie O, Nicholson C, Menon K, Cramp M, McDougall N & Cash J Pradeep A, Barker F, Ramos K, Littlejohn W, Tavabie O, Nicholson C, Menon K, Cramp M, McDougall N & Cash J 'P085 Virtual transplant assessment is feasible and may increase access to liver transplantation' , DOI

Rupar O, Denson J, Jarvis M & Cramp M Rupar O, Denson J, Jarvis M & Cramp M 'P215 Universal tumour antigens in primary liver neoplasms: cholangiocarcinoma and hepatocellular carcinoma differ' , DOI

Tavabie O, Kronsten V, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Prachalias A, Menon K & Agarwal K Tavabie O, Kronsten V, Valliani T, Joshi D, Cash J, Suddle A, Cramp M, Prachalias A, Menon K & Agarwal K 'P98 Formal regional referral networks optimize patient selection for liver transplantation' , DOI

Subhani M, Ramos K, Vine L & Cramp M Subhani M, Ramos K, Vine L & Cramp M 'SAT-122-Cirrhotic cardiomyopathy: An observational study pre-liver transplant' , DOI

Bassendine M, Pagano S, Bridge S, Sheridan D, Shawa I, Cramp M, Taylor-Robinson S, Neely D & Vuilleumier N Bassendine M, Pagano S, Bridge S, Sheridan D, Shawa I, Cramp M, Taylor-Robinson S, Neely D & Vuilleumier N 'SAT-221-Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection' , DOI

Felmlee D, Redondo P, Ow M & Cramp M Felmlee D, Redondo P, Ow M & Cramp M 'Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort' , DOI

Tanase A, Aroori S, Dhanda A, Cramp M & Streeter A Tanase A, Aroori S, Dhanda A, Cramp M & Streeter A 'HPB O07 Complication profile of laparoscopic common bile duct exploration: Results from R-ALiCE Study' , DOI

Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A & Forton DM 'Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment' , DOI

Abellona U, Mark DP, Oleribe O, Ladep N, Reeves H, Greer S, Prince M, Ryder S, Nash K & Cramp M Abellona U, Mark DP, Oleribe O, Ladep N, Reeves H, Greer S, Prince M, Ryder S, Nash K & Cramp M 'Towards elucidating a universal panel of diagnostic biomarkers for early hepatocellular carcinoma' , DOI

Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M 'Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort' , DOI

Profiles

Chair in Hepatology

Peninsula Medical School (Faculty of Health)

Highlights